| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/27/2002 | US20020081286 NRG-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 06/27/2002 | US20020081285 Treatment for diabetes |
| 06/27/2002 | US20020081284 Manipulation of arterial-venous identity |
| 06/27/2002 | US20020081282 Genetically engineered cell comprising DNA encoding a transmembrane LAG-3 protein (lymphocyte activting gene) on its surface resulting in the protection from graft rejection by a host's immune system |
| 06/27/2002 | US20020081280 Virology and gene therapy; modified fiber knob retains its ability to trimerize and retains its native biosynthesis profile |
| 06/27/2002 | US20020081279 In vitro manipulation of a plasmid-cloned chicken embryo lethal orphan (CELO) virus DNA, suitable for the production of vectors for gene therapy and as a vaccine against infectious diseases in human and animals, particularly birds |
| 06/27/2002 | US20020081276 Gene therapy utilizing hematopoietic stem cells, lymphoid progenitor cells and/or myeloid progenitor cells which are genetically modified to provide a gene that is expressed in these cells and their progency after differentiation |
| 06/27/2002 | CA2714357A1 Mutations in neuronal gene sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | CA2433308A1 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r4 |
| 06/27/2002 | CA2432797A1 Local regional chemotherapy and radiotherapy using in situ hydrogel |
| 06/27/2002 | CA2432506A1 Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus |
| 06/27/2002 | CA2432310A1 Electrically responsive promoter system |
| 06/27/2002 | CA2432301A1 Lentiviral vector-mediated gene transfer and uses thereof |
| 06/27/2002 | CA2432157A1 The use of ecm degrading enzymes for the improvement of cell transplantation |
| 06/27/2002 | CA2432036A1 Means for the diagnosis and therapy of ctcl |
| 06/27/2002 | CA2431891A1 Mutations in neuronal gene sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | CA2431884A1 Neocentromere-based mini-chromosomes or artificial chromosomes |
| 06/27/2002 | CA2431139A1 Oxidoreductases |
| 06/27/2002 | CA2430918A1 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | CA2429519A1 Novel human secreted proteins and polynucleotides encoding the same |
| 06/27/2002 | CA2406028A1 Method for testing for allergic disease |
| 06/26/2002 | EP1217067A2 Connective tissue growth factor-2 |
| 06/26/2002 | EP1217007A2 Serum paraoxonase |
| 06/26/2002 | EP1216710A1 The regulation of systemic immune responses utilizing cytokines and antigens |
| 06/26/2002 | EP1216309A2 Methods for targeting rna molecules |
| 06/26/2002 | EP1216302A2 Immunogenic polypeptide derived from moraxella catarrhalis and uses thereof |
| 06/26/2002 | EP1216299A2 Gene transfer in human lymphocytes using retroviral scfv cell targeting |
| 06/26/2002 | EP1216055A2 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 06/26/2002 | EP1216049A2 Methods for treating muscular dystrophy with bone marrow cells |
| 06/26/2002 | EP1083945B1 Encapsulation devices with strand, yarn or mesh core |
| 06/26/2002 | EP1007072A4 Glial cell line-derived neurotrophic factor receptors |
| 06/26/2002 | EP0783296B1 Novel compositions for the introduction of polyanionic materials into cells |
| 06/26/2002 | EP0464147B1 Matrix metalloproteinase inhibitor peptides |
| 06/26/2002 | CN1355851A Paramyxorividae virus vector defective in envelope gene |
| 06/26/2002 | CN1355846A Method for down-regulating IL5 activity |
| 06/26/2002 | CN1355844A Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| 06/26/2002 | CN1355714A LIM Mineralization protein splice variants |
| 06/26/2002 | CN1355712A Use of antibodies against CD2O for treatment of graft versus host disease |
| 06/26/2002 | CN1355706A 因子 Factor |
| 06/26/2002 | CN1355015A Application of liposome preparation in transferring foreign DNA by testis injection |
| 06/25/2002 | US6410723 Nucleotide sequences for use as tools in controlling gene expression |
| 06/25/2002 | US6410722 Nucleotide sequences associate with replication; for use as tool in genetic engineering |
| 06/25/2002 | US6410720 Compounds and methods for treatment and diagnosis of mycobacterial infections |
| 06/25/2002 | US6410709 Polypeptide; for use in diagnosis and treatment of inflammatory and cell proliferative disorders |
| 06/25/2002 | US6410693 Inhibitors of the JNK signal transduction pathway and methods of use |
| 06/25/2002 | US6410688 Def1 |
| 06/25/2002 | US6410645 Multiblock biodegradable hydrogels for drug delivery and tissue treatment |
| 06/25/2002 | US6410517 Targeted gene delivery system |
| 06/25/2002 | US6410509 Antigen; induce immunology response |
| 06/25/2002 | US6410507 Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| 06/25/2002 | US6410506 Transforming growth factor α HII |
| 06/25/2002 | US6410328 Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
| 06/25/2002 | US6410326 Destroying human tumor cells; obtain tumor cells, transform with replication defective vector, incubate with prodrug, monitor destruction of cells |
| 06/25/2002 | US6410320 Kidney stem cells; for use in treatment of kidney defects |
| 06/25/2002 | US6410316 Methods for producing a vector producing cell line utilizing a high multiplicity of transduction |
| 06/25/2002 | US6410314 Episomally replicating vector, its preparation and use |
| 06/25/2002 | US6410300 Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV |
| 06/25/2002 | US6410299 Attenuated forms of bovine viral diarrhea virus |
| 06/25/2002 | US6410297 Processes for preparation of Marek's disease virus using continuous avian cell lines |
| 06/25/2002 | US6410286 Asparaginyl tRNA synthetase from Staphylococcus Aureus |
| 06/25/2002 | US6410273 Generating methylated nucleotide sequences; obtain prokaryotc cell, transform with nucleotide sequences and expression vector, culture cells, recover methylated nucleotide sequences |
| 06/25/2002 | US6410266 Eukaryotic cells for use as tools in genetic engineering |
| 06/25/2002 | US6410263 Histidine kinase |
| 06/25/2002 | US6410257 Methods to assay gene function with viral vectors |
| 06/25/2002 | US6410250 Sustained delivery device and methods of making and using the same |
| 06/25/2002 | US6410238 Hybrid nucleic acids; cancer diagnosis |
| 06/25/2002 | US6410224 Cleavage of protein using enzyme; therapy for inflammation, asthma, rheumatic diseases, autoimmune diseases |
| 06/25/2002 | US6410057 Biodegradable mixed polymeric micelles for drug delivery |
| 06/25/2002 | US6410049 Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery |
| 06/25/2002 | US6410032 Attenuated forms of bovine viral diarrhea virus |
| 06/25/2002 | US6410029 2-methoxyestradiol-induced apoptosis in cancer cells |
| 06/25/2002 | US6410023 Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene |
| 06/25/2002 | US6410015 Selecting from bone marrow-derived cells population responsive to transforming growth factor beta-1, using as vehicles for transferring genes encoding therapeutic protein to mammal |
| 06/25/2002 | US6410014 Administering protein-tyrosine kinase chimeras capable of directing cytotoxic t lymphocytes to specifically recognize and lyse target cells |
| 06/25/2002 | US6410013 Viral vectors for use in monitoring HIV drug resistance |
| 06/25/2002 | US6410012 Antimicrobial mediated bacterial DNA delivery |
| 06/25/2002 | US6410011 Treatment of restenosis by gene therapy, comprising the administration of a recombinant adenovirus containing a suicide gene |
| 06/25/2002 | US6410010 Recombinant P53 adenovirus compositions |
| 06/25/2002 | US6410007 Erectile dysfunction, vasodilation |
| 06/25/2002 | US6409716 Drug delivery |
| 06/25/2002 | CA2245462C Methods of modulating cell proliferation through telomerase modulation |
| 06/25/2002 | CA2201587C Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
| 06/25/2002 | CA2194393C Mammalian telomerase |
| 06/25/2002 | CA2135648C Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 06/25/2002 | CA2095300C Use of genetically modified cells to treat defects, disease or damage of the central nervous system |
| 06/23/2002 | WO2002040654A2 A human serpin secreted from lymphoid cells lsi-01 |
| 06/23/2002 | CA2429179A1 Polynucleotide encoding a novel human serpin secreted from lymphoid cells lsi-01 |
| 06/20/2002 | WO2002048405A2 Non-invasive method for detecting target rna |
| 06/20/2002 | WO2002048397A2 Regulation of human adenylate cyclase, type vii |
| 06/20/2002 | WO2002048384A2 Nucleic acid sequence 'm73791' serving as a human gene, and derivatives thereof |
| 06/20/2002 | WO2002048380A2 Glycosilated cationic lipids for liposomes used in drug delivery |
| 06/20/2002 | WO2002048372A2 Target enzymes |
| 06/20/2002 | WO2002048370A2 Compositions and methods relating to colon specific genes and proteins |
| 06/20/2002 | WO2002048358A2 Regulation of human chemokine-like receptor |
| 06/20/2002 | WO2002048354A1 Tumour suppressor gene identified on chromosome 18 |
| 06/20/2002 | WO2002048353A2 Dna-sequences, which code for an apoptosis signal transduction protein |
| 06/20/2002 | WO2002048351A2 A method for in vitro molecular evolution of protein function |
| 06/20/2002 | WO2002048349A1 Polypeptide capable of binding to heparin |
| 06/20/2002 | WO2002048348A1 Novel gene existing in human leukocyte antigen domain |
| 06/20/2002 | WO2002048344A2 Gene therapy for prostate cancer: sensibilization of cells to dn a damaging drugs and radiation |